Although cocaine binds to several sites in the brain, the biochemical receptor mechanism or mechanisms associated with its dependence producing properties are unknown. It is shown here that the potencies of cocaine-like drugs in self-administration studies correlate with their potencies in inhibiting [3H]mazindol binding to the dopamine transporters in the rat striatum, but not with their potencies in binding to a large number of other presynaptic and postsynaptic binding sites. Thus, the cocaine receptor related to substance abuse is proposed to be the one associated with dopamine uptake inhibition.

The functional role of heteromers of G-protein-coupled receptors is a matter of debate. In the present study, we demonstrate that

The abuse of psychoactive 'bath salts' containing cathinones such as 3,4-methylenedioxypyrovalerone (MDPV) is a growing public health concern, yet little is known about their pharmacology. Here, we evaluated the effects of MDPV and related drugs using molecular, cellular, and whole-animal methods. In vitro transporter assays were performed in rat brain synaptosomes and in cells expressing human transporters, while clearance of endogenous dopamine was measured by fast-scan cyclic voltammetry in mouse striatal slices. Assessments of in vivo neurochemistry, locomotor activity, and cardiovascular parameters were carried out in rats. We found that MDPV blocks uptake of [ 3 H]dopamine (IC 50 ¼ 4.1 nM) and [ 3 H]norepinephrine (IC 50 ¼ 26 nM) with high potency but has weak effects on uptake of [ 3 H]serotonin (IC 50 ¼ 3349 nM). In contrast to other psychoactive cathinones (eg, mephedrone), MDPV is not a transporter substrate. The clearance of endogenous dopamine is inhibited by MDPV and cocaine in a similar manner, but MDPV displays greater potency and efficacy. Consistent with in vitro findings, MDPV (0.1-0.3 mg/kg, intravenous) increases extracellular concentrations of dopamine in the nucleus accumbens. Additionally, MDPV (0.1-3.0 mg/kg, subcutaneous) is at least 10 times more potent than cocaine at producing locomotor activation, tachycardia, and hypertension in rats. Our data show that MDPV is a monoamine transporter blocker with increased potency and selectivity for catecholamines when compared with cocaine. The robust stimulation of dopamine transmission by MDPV predicts serious potential for abuse and may provide a mechanism to explain the adverse effects observed in humans taking high doses of 'bath salts' preparations.

The physiological meaning of the coexpression of adenosine A2A receptors and group I metabotropic glutamate receptors in ␥-aminobutyric acid (GABA)ergic striatal neurons is intriguing. Here we provide in vitro and in vivo evidence for a synergism between adenosine and glutamate based on subtype 5 metabotropic glutamate (mGluR5) and adenosine A2A ( A denosine is a neuromodulator that plays a very important role in basal ganglia function (1). Its actions are mediated by specific G protein-coupled receptors, which are currently classified in A1, A2A, A2B, and A3 subtypes (2). Compared with the other adenosine receptor subtypes, A2A receptors (A2ARs) are concentrated in the striatum (1, 3), where they are expressed mostly by ␥-aminobutyric acid (GABA)ergic striatopallidal neurons (4). The recent ultrastructural analysis performed by Hettinger et al. (5) has demonstrated that, in the rat, A2ARs are localized mostly postsynaptically in the dendrites and dendritic spines of striatal GABAergic neurons. A2AR immunoreactivity was observed primarily at glutamatergic (asymmetric) synapses (5). Therefore, it was suggested that A2AR plays a prominent role in modulating glutamatergic input to striatal GABAergic neurons (5).Glutamate acts on both ionotropic and metabotropic G protein-coupled receptors (mGluRs). Molecular and pharmacological characterization studies have currently divided the mGluR family into three groups (I-III) (6). Group I mGluR includes mGluR1 and mGluR5, with the latter being highly expressed in the striatum, particularly in the striatal GABAergic efferent neurons (7). In the striatopallidal complex in primates, mGluR5 showed a localization very similar to that described for A2AR in rats. Thus, mGluR5 immunoreactivity was commonly found postsynaptically and perisynaptically to asymmetric synapses (8). These studies provide a morphological basis for the possible existence of functional interactions between striatal A2AR and mGluR5. In fact, in recent in vivo microdialysis experiments we found functional evidence for the possible existence of synergistic A2AR͞mGlluR5 interactions modulating the function of the GABAergic striatopallidal neurons originating in the nucleus accumbens (9). In the present study we provide evidence for the existence of A2AR͞mGluR5 heteromeric complexes in membrane preparations from human embryonic kidney (HEK)-293 cells transiently cotransfected with both receptors and from rat striatum. Furthermore, the same kind of functional A2AR͞mGluR5 synergistic interaction (induction of the immediate-early gene c-fos) could be demonstrated both in cotransfected cells and the rat striatum. These results suggest that A2AR͞mGluR5 synergistic interactions can have important implications for striatal neuronal function and dysfunction.